Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of September 7, 2017, the Board of Directors (the “Board”) of Novelion Therapeutics Inc. (the “Company”) appointed Suzanne Bruhn, Ph.D. to serve as a director. Dr. Bruhn’s appointment will take effect on October 1, 2017.

Dr. Bruhn has served as President and Chief Executive Officer of Proclara Biosciences, Inc. since April 2017. Between May 2012 and November 2015, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc. She also served as a member of the board of directors of Raptor Pharmaceuticals Corp., a publicly traded pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016. Prior to that, Dr. Bruhn served as Senior Vice President, Strategic Planning and Program Management at Shire plc, a publicly traded biopharmaceutical company, between December 1998 and February 2012. Dr. Bruhn currently also serves on the board of directors of Aeglea BioTherapeutics, Inc., a publicly traded biotechnology company focused on the treatment of rare genetic diseases and cancer, and Pliant Therapeutics, a private biotechnology company. Dr. Bruhn received her B.S. degree in Chemistry from Iowa State University and her Ph.D. in Chemistry from Massachusetts Institute of Technology.

There is no arrangement or understanding with the Company to which Dr. Bruhn was appointed to the Board, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Dr. Bruhn that would be reportable under Item 404(a) of Regulation S-K. As a director, Dr. Bruhn will participate in the standard compensation plan for non-employee directors as described starting on page 21 of the Proxy Statement for the Company's 2017 annual general meeting of shareholders (the “Proxy Statement”), including a $40,000 annual retainer for her service as a director, which will be prorated for 2017. In addition, as a non-employee director, Dr. Bruhn will be eligible for stock option and other equity awards as well as any retainers or other cash compensation as approved from time to time by the Board, upon the recommendation of the Compensation Committee of the Board. In connection with her appointment and consistent with the arrangements described in the Proxy Statement, Dr. Bruhn will receive a stock option to purchase 9,600 of the Company’s common shares upon the first business day after her appointment date of October 1, 2017, which will vest in equal monthly installments over 36 months, beginning one month after the grant date.

Item 5.02 Regulation FD.

A copy of the press release announcing Dr. Bruhn’s appointment is attached as Exhibit 99.1.

Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 5.02.Financial Statements and Exhibits.

(d)Exhibits.

NOVELION THERAPEUTICS INC. ExhibitEX-99.1 2 pressrelease_bruhnaddition.htm EXHIBIT 99.1 Exhibit Exhibit No. 99.1Novelion Therapeutics Appoints Suzanne Bruhn,…To view the full exhibit click here
About Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.